Education
About Us
Working with TipRanks
Follow Us
Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
Total Valuation
Immix Biopharma has a market cap or net worth of $79.45M. The enterprise value is ―.
Market Cap$79.45M
Enterprise Value―
Share Statistics
Immix Biopharma has 27,877,293 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,877,293
Owned by Insiders39.92%
Owned by Institutions0.09%
Financial Efficiency
Immix Biopharma’s return on equity (ROE) is -1.63 and return on invested capital (ROIC) is -158.58%.
Return on Equity (ROE)-1.63
Return on Assets (ROA)-0.94
Return on Invested Capital (ROIC)-158.58%
Return on Capital Employed (ROCE)-1.59
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count18
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immix Biopharma is ―. Immix Biopharma’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value4.70
Price to FCF0.00
Price to Operating Cash Flow-6.49
PEG Ratio―
Income Statement
In the last 12 months, Immix Biopharma had revenue of 0.00 and earned -21.61M in profits. Earnings per share was -0.76.
Revenue0.00
Gross Profit0.00
Operating Income-22.67M
Pretax Income-21.66M
Net Income-21.61M
EBITDA-21.54M
Earnings Per Share (EPS)-0.76
Cash Flow
In the last 12 months, operating cash flow was -245.95K and capital expenditures 0.00, giving a free cash flow of -245.95K billion.
Operating Cash Flow-245.95K
Free Cash Flow-245.95K
Free Cash Flow per Share>-0.01
Dividends & Yields
Immix Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.55
52-Week Price Change19.50%
50-Day Moving Average2.51
200-Day Moving Average2.04
Relative Strength Index (RSI)41.56
Average Volume (3m)213.30K
Important Dates
Immix Biopharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Immix Biopharma as a current ratio of 2.33, with Debt / Equity ratio of 11.04%
Current Ratio2.33
Quick Ratio2.33
Debt to Market Cap<0.01
Net Debt to EBITDA0.77
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immix Biopharma has paid 41.04K in taxes.
Income Tax41.04K
Effective Tax Rate>-0.01
Enterprise Valuation
Immix Biopharma EV to EBITDA ratio is -2.12, with an EV/FCF ratio of -2.89.
EV to Sales0.00
EV to EBITDA-2.12
EV to Free Cash Flow-2.89
EV to Operating Cash Flow-3.13
Balance Sheet
Immix Biopharma has $15.92M in cash and marketable securities with ― in debt, giving a net cash position of -$14.86M billion.
Cash & Marketable Securities$15.92M
Total Debt―
Net Cash-$14.86M
Net Cash Per Share-$0.53
Tangible Book Value Per Share$0.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immix Biopharma is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside169.23% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―